Publication: Humanized-V<inf>H</inf>H transbodies that inhibit HCV protease and replication
Issued Date
2015-04-20
Resource Type
ISSN
19994915
19994915
19994915
DOI
Other identifier(s)
2-s2.0-84928969170
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Viruses. Vol.7, No.4 (2015), 2030-2056
Suggested Citation
Surasak Jittavisutthikul, Jeeraphong Thanongsaksrikul, Kanyarat Thueng-In, Monrat Chulanetra, Potjanee Srimanote, Watee Seesuay, Aijaz Ahmad Malik, Wanpen Chaicumpa Humanized-V<inf>H</inf>H transbodies that inhibit HCV protease and replication. Viruses. Vol.7, No.4 (2015), 2030-2056. doi:10.3390/v7042030 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36114
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Humanized-V<inf>H</inf>H transbodies that inhibit HCV protease and replication
Other Contributor(s)
Abstract
© 2015 by the authors; licensee MDPI, Basel, Switzerland. There is a need for safe and broadly effective anti-HCV agents that can cope with genetic multiplicity and mutations of the virus. In this study, humanized-camel VHHs to genotype 3a HCV serine protease were produced and were linked molecularly to a cell penetrating peptide, penetratin (PEN). Human hepatic (Huh7) cells transfected with the JFH-1 RNA of HCV genotype 2a and treated with the cell penetrable nanobodies (transbodies) had a marked reduction of the HCV RNA intracellularly and in their culture fluids, less HCV foci inside the cells and less amounts of HCV core antigen in culture supernatants compared with the infected cells cultured in the medium alone. The PEN-VHH-treated-transfected cells also had up-regulation of the genes coding for the host innate immune response (TRIF, TRAF3, IRF3, IL-28B and IFN-β), indicating that the cell penetrable nanobodies rescued the host innate immune response from the HCV mediated-suppression. Computerized intermolecular docking revealed that the VHHs bound to residues of the protease catalytic triad, oxyanion loop and/or the NS3 N-terminal portion important for non-covalent binding of the NS4A protease cofactor protein. The so-produced transbodies have high potential for testing further as a candidate for safe, broadly effective and virus mutation tolerable anti-HCV agents.